Crossover effects of estrogen receptor status on breast cancer-specific hazard rates by age and race.

<h4>Background</h4>Previous studies found that the risk of breast cancer-related death is greater in estrogen receptor (ER)-negative disease than in ER-positive disease within 5 years of diagnosis, but greater for ER-positive disease than for ER-negative disease more than 5 years after d...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Yu Ren, Dalliah M Black, Elizabeth A Mittendorf, Peijun Liu, Xu Li, Xianglin L Du, Jianjun He, Jin Yang, Kelly K Hunt, Min Yi
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2014
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/827844cc6b2446f8857a080b61504c6d
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:827844cc6b2446f8857a080b61504c6d
record_format	dspace
spelling	oai:doaj.org-article:827844cc6b2446f8857a080b61504c6d2021-11-25T05:55:43ZCrossover effects of estrogen receptor status on breast cancer-specific hazard rates by age and race.1932-620310.1371/journal.pone.0110281https://doaj.org/article/827844cc6b2446f8857a080b61504c6d2014-01-01T00:00:00Zhttps://doi.org/10.1371/journal.pone.0110281https://doaj.org/toc/1932-6203<h4>Background</h4>Previous studies found that the risk of breast cancer-related death is greater in estrogen receptor (ER)-negative disease than in ER-positive disease within 5 years of diagnosis, but greater for ER-positive disease than for ER-negative disease more than 5 years after diagnosis. This phenomenon is referred to as ER-positive and -negative crossover. Our aim was to evaluate this crossover by determining the timing of the hazard of breast cancer death by patient, clinical, and tumor factors.<h4>Methods</h4>Patients with breast cancer diagnosed between 1990 and 2005 were identified from the Surveillance, Epidemiology, and End Results database. The cohort was evaluated by age at diagnosis, race, tumor ER status, tumor and nodal stage, and tumor grade. Disease-specific (DS) hazard rates were calculated.<h4>Results</h4>Of the 439,444 patients identified, 77.5% had ER-positive disease. Overall, ER-negative to ER-positive DS hazard rates crossed between the years 7 and 8 after diagnosis. Earlier crossover was linked to black or Hispanic race, young age (<40 years), or tumors that were larger, higher grade, or affected the nodes. Young black (<40 years) patients who had a T3/T4 tumor with positive nodes, grade III or undifferentiated, had the earliest crossover, in year 4.<h4>Conclusions</h4>The timing of crossover of death hazard for ER-positive and ER-negative disease varies by clinical and tumor factors. These findings may help guide recommendations regarding the duration of endocrine therapy for patients with ER-positive cancer.Yu RenDalliah M BlackElizabeth A MittendorfPeijun LiuXu LiXianglin L DuJianjun HeJin YangKelly K HuntMin YiPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 9, Iss 10, p e110281 (2014)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Yu Ren Dalliah M Black Elizabeth A Mittendorf Peijun Liu Xu Li Xianglin L Du Jianjun He Jin Yang Kelly K Hunt Min Yi Crossover effects of estrogen receptor status on breast cancer-specific hazard rates by age and race.
description	<h4>Background</h4>Previous studies found that the risk of breast cancer-related death is greater in estrogen receptor (ER)-negative disease than in ER-positive disease within 5 years of diagnosis, but greater for ER-positive disease than for ER-negative disease more than 5 years after diagnosis. This phenomenon is referred to as ER-positive and -negative crossover. Our aim was to evaluate this crossover by determining the timing of the hazard of breast cancer death by patient, clinical, and tumor factors.<h4>Methods</h4>Patients with breast cancer diagnosed between 1990 and 2005 were identified from the Surveillance, Epidemiology, and End Results database. The cohort was evaluated by age at diagnosis, race, tumor ER status, tumor and nodal stage, and tumor grade. Disease-specific (DS) hazard rates were calculated.<h4>Results</h4>Of the 439,444 patients identified, 77.5% had ER-positive disease. Overall, ER-negative to ER-positive DS hazard rates crossed between the years 7 and 8 after diagnosis. Earlier crossover was linked to black or Hispanic race, young age (<40 years), or tumors that were larger, higher grade, or affected the nodes. Young black (<40 years) patients who had a T3/T4 tumor with positive nodes, grade III or undifferentiated, had the earliest crossover, in year 4.<h4>Conclusions</h4>The timing of crossover of death hazard for ER-positive and ER-negative disease varies by clinical and tumor factors. These findings may help guide recommendations regarding the duration of endocrine therapy for patients with ER-positive cancer.
format	article
author	Yu Ren Dalliah M Black Elizabeth A Mittendorf Peijun Liu Xu Li Xianglin L Du Jianjun He Jin Yang Kelly K Hunt Min Yi
author_facet	Yu Ren Dalliah M Black Elizabeth A Mittendorf Peijun Liu Xu Li Xianglin L Du Jianjun He Jin Yang Kelly K Hunt Min Yi
author_sort	Yu Ren
title	Crossover effects of estrogen receptor status on breast cancer-specific hazard rates by age and race.
title_short	Crossover effects of estrogen receptor status on breast cancer-specific hazard rates by age and race.
title_full	Crossover effects of estrogen receptor status on breast cancer-specific hazard rates by age and race.
title_fullStr	Crossover effects of estrogen receptor status on breast cancer-specific hazard rates by age and race.
title_full_unstemmed	Crossover effects of estrogen receptor status on breast cancer-specific hazard rates by age and race.
title_sort	crossover effects of estrogen receptor status on breast cancer-specific hazard rates by age and race.
publisher	Public Library of Science (PLoS)
publishDate	2014
url	https://doaj.org/article/827844cc6b2446f8857a080b61504c6d
work_keys_str_mv	AT yuren crossovereffectsofestrogenreceptorstatusonbreastcancerspecifichazardratesbyageandrace AT dalliahmblack crossovereffectsofestrogenreceptorstatusonbreastcancerspecifichazardratesbyageandrace AT elizabethamittendorf crossovereffectsofestrogenreceptorstatusonbreastcancerspecifichazardratesbyageandrace AT peijunliu crossovereffectsofestrogenreceptorstatusonbreastcancerspecifichazardratesbyageandrace AT xuli crossovereffectsofestrogenreceptorstatusonbreastcancerspecifichazardratesbyageandrace AT xianglinldu crossovereffectsofestrogenreceptorstatusonbreastcancerspecifichazardratesbyageandrace AT jianjunhe crossovereffectsofestrogenreceptorstatusonbreastcancerspecifichazardratesbyageandrace AT jinyang crossovereffectsofestrogenreceptorstatusonbreastcancerspecifichazardratesbyageandrace AT kellykhunt crossovereffectsofestrogenreceptorstatusonbreastcancerspecifichazardratesbyageandrace AT minyi crossovereffectsofestrogenreceptorstatusonbreastcancerspecifichazardratesbyageandrace
_version_	1718414351921053696

Crossover effects of estrogen receptor status on breast cancer-specific hazard rates by age and race.

Ejemplares similares